|
Basic Characteristics of Mutations
|
|
Mutation Site
|
Q493R |
|
Mutation Site Sentence
|
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
COVID-19
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
bamlanivimab;etesivimab |
|
Location
|
Italy |
|
Literature Information
|
|
PMID
|
34314668
|
|
Title
|
Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
|
|
Author
|
Focosi D,Novazzi F,Genoni A,Dentali F,Gasperina DD,Baj A,Maggi F
|
|
Journal
|
Emerging infectious diseases
|
|
Journal Info
|
2021 Oct;27(10):2728-2731
|
|
Abstract
|
We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.
|
|
Sequence Data
|
MZ157275
|